UA79267C2 - Peroral composition of solid solution of poorly water-soluble active substance and process for its preparation - Google Patents

Peroral composition of solid solution of poorly water-soluble active substance and process for its preparation Download PDF

Info

Publication number
UA79267C2
UA79267C2 UA20040907457A UA20040907457A UA79267C2 UA 79267 C2 UA79267 C2 UA 79267C2 UA 20040907457 A UA20040907457 A UA 20040907457A UA 20040907457 A UA20040907457 A UA 20040907457A UA 79267 C2 UA79267 C2 UA 79267C2
Authority
UA
Ukraine
Prior art keywords
mixture
active substance
alkyl
composition
immediate
Prior art date
Application number
UA20040907457A
Other languages
English (en)
Ukrainian (uk)
Inventor
Henricus R M Gorissen
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of UA79267C2 publication Critical patent/UA79267C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UA20040907457A 2002-02-14 2003-11-02 Peroral composition of solid solution of poorly water-soluble active substance and process for its preparation UA79267C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02075623 2002-02-14
PCT/EP2003/050014 WO2003068266A1 (en) 2002-02-14 2003-02-11 Oral solid solution formulation of a poorly water-soluble active substance

Publications (1)

Publication Number Publication Date
UA79267C2 true UA79267C2 (en) 2007-06-11

Family

ID=27619166

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20040907457A UA79267C2 (en) 2002-02-14 2003-11-02 Peroral composition of solid solution of poorly water-soluble active substance and process for its preparation

Country Status (24)

Country Link
US (2) US20050008697A1 (de)
EP (1) EP1476196B1 (de)
JP (1) JP2005517041A (de)
KR (1) KR101014545B1 (de)
CN (1) CN1273194C (de)
AR (1) AR038681A1 (de)
AT (1) ATE345817T1 (de)
AU (1) AU2003208713B2 (de)
BR (1) BR0307278A (de)
CA (1) CA2472744A1 (de)
DE (1) DE60309839T2 (de)
DK (1) DK1476196T3 (de)
ES (1) ES2277635T3 (de)
HR (1) HRP20040613A2 (de)
IL (2) IL162883A0 (de)
MX (1) MXPA04007852A (de)
NO (1) NO20043832L (de)
PL (1) PL370452A1 (de)
PT (1) PT1476196E (de)
RU (1) RU2314811C2 (de)
SI (1) SI1476196T1 (de)
UA (1) UA79267C2 (de)
WO (1) WO2003068266A1 (de)
ZA (1) ZA200405608B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
TW200633713A (en) * 2004-12-23 2006-10-01 Solvay Pharm Bv Oral immediate release formulation of a poorly water-soluble active substance
WO2007054975A1 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP2007308479A (ja) 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 固体分散体製剤
AU2007259252A1 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Oral pharmaceutical composition of a poorly water-soluble active substance
KR20090033246A (ko) * 2006-06-22 2009-04-01 솔베이 파마슈티칼스 비. 브이 수용성이 불량한 활성 물질의 경구용 약제학적 조성물
CA2656903A1 (en) * 2006-07-06 2008-01-10 Ares Trading S.A. An oral pharmaceutical composition of anilinopyrimidine, preparation and use thereof
JP2010501642A (ja) * 2006-09-01 2010-01-21 テバ ファーマシューティカル インダストリーズ リミティド カルシウム受容体−活性化合物の固体複合材料
AR071375A1 (es) * 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
KR20130097173A (ko) 2010-08-04 2013-09-02 그뤼넨탈 게엠베하 신경병증성 통증을 치료하기 위한 ６’­플루오로­（Ｎ­메틸­ 또는 Ｎ，Ｎ­디메틸­）­４­페닐­４’，９’­디하이드로­３’Ｈ­스피로[사이클로헥산­１，１’­피라노[３，４，ｂ]인돌]­４­아민을 포함하는 약제학적 투여형
WO2012016699A2 (en) * 2010-08-04 2012-02-09 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4,9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine
WO2017004733A1 (zh) * 2015-07-03 2017-01-12 浙江海正药业股份有限公司 一种人参皂苷c-k口服固体制剂及其制备方法
PL424452A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
PL424453A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
WO2020112961A1 (en) * 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations
WO2025018777A1 (ko) * 2023-07-18 2025-01-23 삼아제약 주식회사 프란루카스트 함유 약제학적 조성물의 제조방법 및 상기 제조방법에 의해 제조된 약제학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3359167A (en) * 1965-07-22 1967-12-19 Pfizer & Co C Vitamin a compositions
CU35543A1 (es) * 1980-10-09 1983-05-05 Hoffmann La Roche Prostaglandines
NZ224497A (en) * 1987-05-18 1990-04-26 Janssen Pharmaceutica Nv Pharmaceutical composition comprising flunarizine
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
SK285019B6 (sk) * 1997-01-30 2006-04-06 Novartis Ag Tvrdá želatínová tobolka
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions

Also Published As

Publication number Publication date
DE60309839T2 (de) 2007-03-15
CN1273194C (zh) 2006-09-06
JP2005517041A (ja) 2005-06-09
ATE345817T1 (de) 2006-12-15
IL162883A (en) 2009-05-04
MXPA04007852A (es) 2004-10-15
CN1633307A (zh) 2005-06-29
ZA200405608B (en) 2005-06-24
IL162883A0 (en) 2005-11-20
ES2277635T3 (es) 2007-07-16
SI1476196T1 (sl) 2007-04-30
EP1476196A1 (de) 2004-11-17
US20050008697A1 (en) 2005-01-13
NO20043832L (no) 2004-09-13
DE60309839D1 (de) 2007-01-04
AR038681A1 (es) 2005-01-26
US20110086844A1 (en) 2011-04-14
DK1476196T3 (da) 2007-03-05
EP1476196B1 (de) 2006-11-22
KR20040085193A (ko) 2004-10-07
RU2004127457A (ru) 2005-04-20
BR0307278A (pt) 2004-12-28
AU2003208713A1 (en) 2003-09-04
WO2003068266A1 (en) 2003-08-21
AU2003208713B2 (en) 2007-10-18
CA2472744A1 (en) 2003-08-21
RU2314811C2 (ru) 2008-01-20
KR101014545B1 (ko) 2011-02-16
AU2003208713B9 (en) 2003-09-04
PT1476196E (pt) 2007-02-28
HRP20040613A2 (en) 2005-04-30
PL370452A1 (en) 2005-05-30
HK1077218A1 (en) 2006-02-10

Similar Documents

Publication Publication Date Title
UA79267C2 (en) Peroral composition of solid solution of poorly water-soluble active substance and process for its preparation
JP3805797B2 (ja) Ｎ−ピペリジノ−３−ピラゾールカルボキサミド誘導体、その塩およびそれらの溶媒和物の経口投与用医薬組成物
AU2690384A (en) Soft gelatin capsules and fill achieving optimum hardness and flexability during storage
JP2002529397A5 (de)
NO333369B1 (no) Fremgangsmate for a oke konsentrasjonen av en farmasoytisk aktiv bestanddel i forhold til fyllpreparat-viskositet for doseenheter og myk gelatinkapsel
JP2008024700A (ja) ベルベリン含有水性組成物
MXPA03002769A (es) Formulacion farmaceutica de liberacion sostenida e independiente de la densidad ionica.
UA77736C2 (en) Pharmaceutical composition based on azetidine derivatives
AP1192A (en) Solubilized sertraline compositions.
JP5276591B2 (ja) ピレノキシン含有二液性点眼剤
Maheswari et al. Formulation and evaluation of controlled porosity osmotic tablets of lornoxicam
JP5918895B1 (ja) ナルフラフィン塩酸塩含有カプセル製剤
JPH0517356A (ja) 硬カプセル剤
JP2011026212A (ja) 保存安定性に優れ、良好な打錠性を有するフルボキサミンマレイン酸塩錠剤
Abdelaziz et al. The wetting of surface‐treated silicone impression materials by gypsum mixes containing disinfectants and modifiers
ES2822992T3 (es) Formulación farmacéutica de racecadotrilo
JP2008031165A (ja) ビタミンａ類を含有する水性組成物
Maddela et al. Formulation and Evaluation of Piroxicam Liquid FillFormulations
JPH0830010B2 (ja) ピコスルフアートナトリウム液充填硬カプセル剤
HK40052698A (en) Pharmaceutical composition of prolyl hydroxylase inhibitor and preparation method therefor
JP2008001660A (ja) ジフェンヒドラミン含有水性組成物
CN113056262A (zh) 一种脯氨酰羟化酶抑制剂的药物组合物及其制备方法
JPH0160451B2 (de)
NZ501250A (en) Solubilized sertraline compositions
JP2017014119A (ja) 経口医薬組成物